COVID-19 in Patients with Oncohematological Diseases

AA Danilenko, SV Shakhtarina, NA Falaleeva

AF Tsyb Medical Radiological Research Centre, branch of the NMRC of Radiology, 4 Koroleva str., Obninsk, Kaluga Region, Russian Federation, 249036

For correspondence: Anatolii Aleksandrovich Danilenko, MD, PhD, 4 Koroleva str., Obninsk, Kaluga Region, Russian Federation, 249036; Tel.: +7(909)250-18-10; e-mail:

For citation: Danilenko AA, Shakhtarina SV, Falaleeva NA. COVID-19 in Patients with Oncohematological Diseases. Clinical oncohematology. 2021;14(2):220–4. (In Russ).

DOI: 10.21320/2500-2139-2021-14-2-220-224


After initially appearing in Wuhan (China), the COVID-19 epidemic rapidly escalated to pandemic level. Due to its high mortality COVID-19 belongs to the group of the most dangerous viral infectious diseases of today. While elderly people are at greatest risk of death, some comorbidities, including also malignant tumors, considerably worsen the course of COVID-19. In view of inherent immunodeficiency exacerbated by immunosuppressive chemotherapy, oncohematological diseases most greatly affect the course of COVID-19. The review presents few published data on coronavirus disease affecting the prognosis of hematopoietic and lymphoid tumors. In addition, the control of mortality risk in these patients is discussed.

Keywords: SARS-CoV-2, COVID-19, hematological diseases, mortality rate.

Received: October 13, 2020

Accepted: February 15, 2021

Read in PDF

Статистика Plumx английский


  1. Johns Hopkins University of Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available from: Accessed 02.2021.
  2. Rassy E, Khoury-Abboud R-M, Ibrahim N, et al. What the oncologist needs to know about COVID-19 infection in cancer patients. Fut Oncol. 2020;16(17):1153–6. doi: 10.2217/fon-2020-0312.
  3. Mina A, van Besien K, Platanias LC, et al. Hematological manifestations of COVID-19. Leuk Lymphoma. 2020;61(12):2790–8. doi: 10.1080/10428194.2020.1788017.
  4. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle Region – case series. N Engl J Med. 2020;382(21):2012–22. doi: 10.1056/nejmoa2004500.
  5. Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762–69. doi: 10.1093/infdis/jiaa150.
  6. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. doi: 10.1056/NEJMoa2002032.
  7. Maquet J, Lafaurie M, Sommet A, et al. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. Br J Haematol. 2020;190(5):e276–е279. doi: 10.1111/bjh.16950.
  8. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–8. doi: 10.1016/j.cca.2020.03.022.
  9. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–4. doi: 10.1111/jth.14830.
  10. Klok FA, Kruip MJ, van der Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7. doi: 10.1016/j.thromres.2020.04.013.
  11. Friman V, Winqvist O, Blimark C, et al. Secondary immunodeficiency in lymphoproliferative malignancies. Hematol Oncol. 2016;34(3):121–32. doi: 10.1002/hon.2323.
  12. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza a (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769–71. doi: 10/1182/blood-2011-08-372649.
  13. Tepasse P-R, Hafezi W, Lutz M, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 2020;190(2):185–8. doi: 10.1111/bjh.16896.
  14. Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of Venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371–9. doi: 10.1158/1078-0432.CCR-17-3761.
  15. Van de Haar J, Hoes LR, Coles CE, et al. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020;26(5):665–71. doi: 10.1038/s41591-020-0874-8.
  16. Lee LYW, Cazier J-B, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309–16. doi: 10.1016/S1470-2045(20)30442-3.
  17. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904–13. doi: 10.1016/S1470-2045(20)30310-7.
  18. Booth S, Willan J, Wong H, et al. Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy. Eur J Haematol. 2020;105(4):476–83. doi: 10.1111/ejh.13469.
  19. Wu Y, Chen W, Li W, et al. Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies. Leuk Lymphoma. 2020;61(14):3440–50. doi: 10.1080/10428194.2020.1808204.
  20. Sanchez-Pina JM, Rodriguez RM, Castro Quismondo N, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020;105(5):597–607. doi: 10.1111/ejh.13493.
  21. Yigenoglu TN, Ata N, Altuntas F, et al. The Outcome of COVID-19 in Patients with Hematological Malignancy. J Med Virol. 2021;93(2):1099–104. doi: 10.1002/jmv.26404.
  22. He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–45. doi: 10.1038/s41375-020-0836-7.
  23. Aries JA, Davies JK, Auer LR, et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol. 2020;190(2):64–7. doi: 10.1111/bjh.16852.
  24. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745. doi: 10.1016/S2352-3026(20)30251-9.
  25. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–43. doi: 10.1182/blood.2020006965.
  26. Haroon A, Alassani M, Aljurf M, et al. COVID-19 post Hematopoietic Cell Transplant, a Report of 11 Cases from a Single Center. Mediterr J Hematol Infect Dis. 2020;12(1):e2020070. doi: 10.4084/MJHID.2020.070.
  27. Shah GL, De Wolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130(12):6656–67. doi: 10.1172/jci141777.
  28. Perini GF, Fischer T, Gaiolla RD, et al. How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell Ther. 2020;42(2):103–10. doi: 10.1016/j.htct.2020.04.002.
  29. Di Ciaccio P, McCaughan G, Trotman J, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J. 2020;50(6):667–79. doi: 10.1111/imj.14859.
  30. De la Cruz-Benito B, Lazaro-Del Campo P, Ramirez-Lopez A, et al. Managing the front-line treatment for diffuse large B-cell lymphoma and high-grade B-cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020;191(3):386–9. doi: 10.1111/bjh.17066.
  31. Yahalom J, Dabaja BS, Ricardi U, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020;135(21):1829–32. doi: 10.1182/blood.2020006028.
  32. Vordermark D. Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups. Radiat Oncol. 2020;15(1):140. doi: 10.1186/s13014-020-01579-3.